Floatz logo

212-lead pentixather

Carcinoid Tumor Lung

Yusuf MendaradiopharmaceuticalEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Carcinoid Tumor Lung cohort.

Asset / SponsorPhaseRating
Temsirolimus
National Cancer Institute (NCI)
Phase 2BB
Regorafenib
University of Southern California
Phase 2B
gw786034
National Cancer Institute (NCI)
Phase 2B
Romidepsin
National Cancer Institute (NCI)
Phase 2CCC
DOTATOC
British Columbia Cancer Agency
Phase 2CCC

View all 16 →

Same molecule, other indications

212-lead pentixather is also rated in:

lung neuroendocrine neoplasmDormant
C
Indicative ·
39 / 100
View asset →
small cell lung carcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →